MetaCap

Alkermes (ALKS) vs Axsome Therapeutics (AXSM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alkermes (ALKS) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 57.1% versus a loss of 13.4%. Over five years, AXSM leads with a +250.4% price change compared with +100.0% for ALKS. Alkermes is the larger company by market cap ($7.55 billion vs $6.80 billion), about 1.1 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs -5.2%).

On valuation, Alkermes trades at a lower forward P/E (33.2x vs 35.5x for Axsome Therapeutics). Alkermes converts more of its revenue into profit, with a net margin of 16.4% versus -28.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALKS+57.08%AXSM-13.44%
+98%+40%-19%
Nov 21, 20251 yearNov 20, 2026
ALKS+93.37%AXSM+261.34%
+645%+288%-69%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALKS versus AXSM key metrics
MetricALKSAXSM
Share price$44.94$129.36
Market cap$7.55B$6.80B
1-day change-2.69%-4.66%
YTD return+60.61%-29.17%
1-year return+57.08%-13.44%
5-year return+100.00%+250.38%
Forward P/E33.2135.47
EPS (TTM)$-0.01$-3.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.48B$638.50M
Revenue growth (YoY)-5.25%+65.55%
Net income (latest FY)$241.66M$-183.17M
Gross margin86.69%92.56%
Operating margin17.21%-26.12%
Net margin16.37%-28.69%
52-week high$55.67$260.19
52-week low$27.00$123.00
Distance from 52-week high-19.27%-50.28%
Analyst consensusbuystrong_buy
Avg. price target upside+28.48%+104.56%
Average volume1.90M865.33K
Shares outstanding168.04M52.60M
Employees2,0501,390
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALKS has outperformed AXSM by 70.5 percentage points over the past year.
  • Alkermes is more profitable, keeping 16.4 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
  • Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs -5.25%).

About Alkermes

ALKS stock →

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees

About Axsome Therapeutics

AXSM stock →

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,390 employees

ALKS vs AXSM FAQ

Which is bigger, Alkermes or Axsome Therapeutics?

Alkermes (ALKS) is larger, with a market capitalization of $7.55B compared with $6.80B for Axsome Therapeutics (AXSM).

Which stock has performed better over the past year, ALKS or AXSM?

ALKS returned +57.08% over the past 12 months, compared with -13.44% for AXSM (price return, excluding dividends). Past performance does not predict future results.

Are Alkermes and Axsome Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons